• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Ghent University Hospital - Product Pipeline Review - Q4 2010 Product Image

Ghent University Hospital - Product Pipeline Review - Q4 2010

  • Published: December 2010
  • 40 pages
  • Global Markets Direct

Ghent University Hospital – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Ghent University Hospital – Developmental Therapeutics Review – Q4 2010” provides data on the institute’s research and development focus. The report includes information on therapeutics under development, complete with latest updates, and features on discontinued projects (if applicable).

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, institute’s website, and featured press releases, both from institute and industry-specific third party sources, put together by Global Markets Direct’s team of industry experts.

Scope

- Review of therapeutics under development by Ghent University Hospital.
- Overview of products under development across various therapy areas.
- Coverage of therapeutic molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Ghent University Hospital with complete READ MORE >



List of Tables
List of Figures
Ghent University Hospital Snapshot
Ghent University Hospital Overview
Key Information
Key Facts
Ghent University Hospital – Research and Development Overview
Key Therapeutic Areas
Ghent University Hospital – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Ghent University Hospital – Pipeline Products Glance
Ghent University Hospital – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Ghent University Hospital Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Ghent University Hospital – Drug Profiles
dexmedetomidine
Product Description
Mechanism of Action
R&D Progress
Losartan
Product Description
Mechanism of Action
R&D Progress
Adalimumab
Product Description
Mechanism of Action
R&D Progress
Aromatase inhibition
Product Description
Mechanism of Action
R&D Progress
Cetuximab (Erbitux)
Product Description
Mechanism of Action
R&D Progress
Doxycycline
Product Description
Mechanism of Action
R&D Progress
FOLFIRI_
Product Description
Mechanism of Action
R&D Progress
Gemcitabine + Oxaliplatin + radiation theraphy
Product Description
Mechanism of Action
R&D Progress
Lanreotide for Malignant Intestinal Obstruction
Product Description
Mechanism of Action
R&D Progress
Methylprednisolone
Product Description
Mechanism of Action
R&D Progress
Moxifloxacin
Product Description
Mechanism of Action
R&D Progress
Nitroglycerin
Product Description
Mechanism of Action
R&D Progress
Nitroglycerine
Product Description
Mechanism of Action
R&D Progress
Nitroprusside
Product Description
Mechanism of Action
R&D Progress
Sevoflurane
Product Description
Mechanism of Action
R&D Progress
Tiotropium bromide
Product Description
Mechanism of Action
R&D Progress
Ghent University Hospital – Pipeline Analysis
Ghent University Hospital – Pipeline Products by Therapeutic Class
Ghent University Hospital Pipeline Products By Target
Ghent University Hospital – Pipeline Products by Route of Administration
Ghent University Hospital – Pipeline Products by Molecule Type
Ghent University Hospital - Dormant Projects
Ghent University Hospital – Locations And Subsidiaries
Head Office
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Format Properties
Electronic (PDF) The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.
Site License The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.
Enterprisewide The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.
Note: Product cover images may vary from those shown
More

RELATED PRODUCTS